Objective To estimate an upper bound on the risk of death after a brief resolved unexplained event (BRUE), a sudden alteration in an infant's breathing, color, tone, or responsiveness, previously labeled "apparent lifethreatening event" (ALTE).
The definitions of BRUE and ALTE overlap but are not identical. The main difference is that to be labeled a BRUE, an event must be "unexplained" after an appropriate history and physical examination. If the diagnosis becomes quickly apparent-for example, when the presentation and initial testing strongly suggest a seizure disorder or serious infection-the ALTE would not qualify as a BRUE.
The 2016 AAP guideline offers explicit recommendations concerning the initial evaluation and management of infants who have experienced a BRUE. Parents typically report that their baby had been struggling to breathe or seemed to have lost consciousness briefly, but the infants often appear well upon arrival at the emergency department. 5 If the clinician cannot find a clear explanation for the event, the situation presents a dilemma. Admission to the hospital for a more extensive investigation is unlikely to yield an answer, but sending the infant home with serious undetected pathology could potentially have grave consequences. The AAP guideline addresses this dilemma by defining a "lower-risk" category of BRUE and suggesting that these patients may be safely discharged home from the emergency department after limited testing and observation. The guideline does not, however, cite the actual likelihood of death after a BRUE, or the likelihood within the subset of infants classified "lower-risk." According to the guideline, a patient may be classified lower-risk if the infant was not premature, has reached 2 months of age, and has not previously experienced a BRUE; the event lasted less than 1 minute and did not require cardiopulmonary resuscitation by a trained medical professional; and other details of the initial history and physical examination are unremarkable.
A few epidemiologic studies have sought to quantify the risk of death after an ALTE, [5] [6] [7] but sample sizes have been insufficient to produce a meaningful risk estimate, given the low incidence of the outcome. A valid estimate would
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American Academy of Pediatrics ALTE Apparent life-threatening event BRUE Brief resolved unexplained event provide a reasonable upper bound on the risk of death after a BRUE because BRUE patients comprise a relatively benign subset of ALTE patients. Lacking such an estimate, clinicians have had no empirical basis for reassuring parents of infants who have experienced a lower-risk BRUE that it is safe to return home from the emergency department with their baby. The purpose of the present investigation was to pool data from all relevant epidemiologic studies to accumulate an adequate sample for generating a valid risk estimate.
Methods
For this meta-analysis, we sought to include every observational cohort study of infants seen in an emergency department after experiencing an ALTE if the research protocol included collection of data on in-hospital and postdischarge deaths and at least 1 week of follow-up after hospital discharge. Guided by the reporting recommendations of the PRISMA group, 8 we began by considering the 55 articles included in a previously published comprehensive review of the literature on the management of ALTEs from 1970 through 2011 9 and a subsequent update through 2014 1 ( Figure) . We also examined the bibliographies of these 55 articles, which yielded 2 more potentially relevant studies that had not been included in the original or updated review. Next, we searched for articles published after 2014 by conducting a PubMed query covering the period January 1, 2015 through February 28, 2017. This search returned 53 articles having at least 1 of the following terms in the title or abstract: apparent life-threating event, ALTE, brief resolved unexplained event, or BRUE. Each investigator independently screened the 53 titles and abstracts, yielding 12 studies judged by at least one of us to be potentially relevant. (A few of the articles were published in a language other than English, but it was clear from the Englishlanguage abstracts that the studies were not relevant.) Finally, each of us independently reviewed the full-text methods sections of the 69 candidate articles to determine which studies met the above-listed follow-up and data collection requirements. After discussion, we agreed that 12 of the 69 studies (17.4%) met the requirements. Different articles sometimes presented analyses based on the same series of patients or different subsets of a larger parent series. In such cases, only the principal article associated with the main series was used in the meta-analysis. This policy prevented the inclusion of any patient more than once in the pooled patient population.
Each of the 12 studies reported number of patients, number of deaths, and length of follow-up or time to death ( Table I) . To compute total patient-months of follow-up for a given study, we used the study's reported follow-up time for each surviving patient and the postevent survival time for patients who died. Study-specific death rates along with exact 2-sided 95% CIs were computed via Poisson regression models. To calculate the overall postevent death rate, we used the NLMIXED procedure in SAS v 9.3 (SAS Institute Inc, Cary, North Carolina) to estimate a Poisson-normal random effects model, 19 which is akin to a random intercept Poisson regression model with offset variable log (person-months). This model allows the true incidence rate to differ across studies and uses an exact likelihood approach that is advantageous when analyzing sparse count data.
Given the different definitions of ALTE and BRUE, a risk estimate derived from the ALTE literature must be adjusted when applied to BRUE patients. Because the BRUE population comprises a relatively benign subset of all ALTEs-most patients with serious conditions, such as sepsis or child abuse, would be excluded-the derived estimate will tend to overestimate mortality after a BRUE. This effect will be magnified when the estimate is applied to lower-risk BRUE patients who, in turn, comprise a relatively benign subset of all BRUEs. It follows that the mortality estimate derived from the metaanalysis must be regarded as an upper bound on the actual probability of death after an event classified as a lower-risk BRUE.
Results
The 12 studies included in the meta-analysis (n = 3005) reported 12 deaths. The Poisson-normal model generated a mortality estimate of 1.8 postevent deaths per 10 000 patientmonths of follow-up (95% CI, 0.5-6.7 deaths per 10 000 patientmonths) or, more intuitively, 1.8 postevent deaths per month of follow-up per 10 000 events.
The above analysis included all reported deaths without regard to the time elapsed since the event. Several babies died in the hospital within a few days of the event, but most deaths occurred weeks, months, or years later (Table II) . A death occurring more than 4 months after a BRUE would not, in all likelihood, be related to the condition that prompted the BRUE and have been preventable by measures that could have been taken during the initial hospitalization. A more relevant risk calculation would, therefore, exclude such delayed deaths.
An analysis that excludes delayed deaths must also truncate the at-risk period (patient-months of follow-up) by specifying a 4-month time horizon. Of the 12 reported deaths, 8 occurred within 3 months of the ALTE (cases 1-8). The 4 remaining deaths occurred between 4 months and 5.5 years after the event. Applying a Poisson-normal model to the 8 proximate deaths using a 4-month time horizon yielded a mortality rate of 3.1 postevent deaths per month per 10 000 events (Table III) .
Using a fixed time horizon makes it possible to convert the deaths-per-month-per-10 000 events metric to a form that should be easier for most parents and clinicians to interpret. Assuming a 4-month time horizon, the upper bound of the risk of death after a BRUE is about 1 in 800 (10 000/ [3.1 × 4] ≈ 800). For comparison, according to US infant mortality statistics gathered between 1999 and 2015, the baseline ). This search identified 2 postdischarge deaths. Adding these to the 3 in-hospital deaths reported in the article brings the total to 5. †In addition to the follow-up protocol described in study 7, the study's senior author was able to confirm that no study patient had died suddenly within 12 months of discharge from the hospital (personal communication, January 11, 2017). As the physician in charge of the sudden infant death program for the entire province of Quebec, Canada, where the study hospital was located, she reviewed all sudden deaths of children under 2 years of age. In this capacity, she would have learned about the sudden death of any study patient.
risk of infant death over a 4-month time interval is about 1 in 500 (or 1 in 1200 after excluding neonatal deaths [age <28 days]). 20 Because the guideline's lower-risk BRUE category excludes patients less than 60 days old, non-neonatal mortality is a more appropriate comparator for the lower-risk group than unrestricted infant mortality. The substantial difference between these 2 death rates reflects the dramatic drop in infant mortality after the neonatal period.
Discussion
Parents who have witnessed an alarming, sometimes terrifying event seek reassurance that their child is not going to experience another, similar event that proves to be fatal. The 2016 AAP guideline states that the risk of death after a BRUE is extremely low in a patient who appears well on presentation and has an unremarkable clinical assessment.
1 Until now, however, the actual risk of death has eluded quantification. 9 Clinicians have, therefore, lacked the evidence needed to explain the meaning of "extremely low" or reassure parents that it is safe to take their baby home from the emergency department after a benign evaluation, as recommended by the guideline.
The present meta-analysis was undertaken to assemble the pertinent evidence. The analysis used survival methods that support mortality estimation from multiple studies with varying lengths of follow-up and potentially disparate underlying death rates because of discrepant case definitions. This approach yielded an estimated 1-in-800 risk of death within 4 months of an ALTE, which constitutes an upper bound on the probability of death after a lower-risk BRUE. Although this estimate is based on the best available evidence, additional studies are needed to increase its precision (Table III) .
Infant mortality statistics provide a frame of reference for gauging how much incremental threat a child faces as a result of having experienced a BRUE. If the reference statistic includes all infant deaths, the occurrence of a BRUE does not appear to increase a child's risk over the baseline risk of 1 in 500. If the reference statistic excludes neonatal deaths, the occurrence of a BRUE appears to increase the risk of death by about 50%, given the non-neonatal baseline risk of 1 in 1200. In a well-appearing BRUE patient classified "lower-risk" by the guideline, however, the probability of death is probably closer to the 1-in-1200 reference statistic that excludes neonatal deaths. The reason is that the 1-in-800 estimate was derived from a heterogeneous pool of ALTE patients that included some patients who would not qualify as BRUEs and some BRUE patients who would not qualify as lower-risk. In a lower-risk patient, therefore, the probability of death likely falls between 1 in 800 and 1 in 1200. Although no amount of evidence can guarantee a good outcome for every such child, a threat of this magnitude would suggest support for the recommendation that routine hospitalization is not needed in the absence of suggestive findings. Ideally, it would be possible to specify separate post-BRUE mortality rates for patients who fit the guideline's higherrisk and lower-risk categories, but deriving risk-stratified rates would require detailed patient-level data to classify every subject into 1 of the 2 categories-data that are not available from the 12 published studies. Given the low order of magnitude of the unstratified risk estimate derived from the meta-analysis, however, a stratified analysis would not be likely to alter the main conclusion of the research.
Several potential threats to validity need to be acknowledged. First, the search strategy may have missed pertinent studies in spite of the authors' efforts. Second, the tracking of deaths was a primary aim in only a few of the studies. The aggressiveness of follow-up varied, depending on the goals of the research, so it is possible that some deaths were overlooked.
Third, findings will need to be applied cautiously in parts of the world not represented by the study hospitals, which are located in the US, Canada, the United Kingdom, Italy, and Israel.
The low post-BRUE risk of death estimated from this metaanalysis justifies the return-home approach advocated in the 2016 AAP guideline for patients assessed as low risk. It may reassure parents to know that, in spite of their understandable fears, the occurrence of a BRUE should not, in itself, be construed as a warning sign that their baby faces a continuing danger. Instead, the evidence indicates that their child's risk is about the same as the baseline risk of death in the overall population during the first year of life. ■ Submitted for publication Sep 29, 2017; last revision received Nov 16, 2017; accepted Dec 14, 2017 
